« Return to News | Miscellaneous | Technology Solutions

’09 Acquisitions Bring Phase Forward Revenues Up, Profits Down

Friday, February 5, 2010 10:19 AM

Phase Forward’s fourth quarter revenues jumped 22% but profits went down, the company reported Thursday night. Phase Forward’s share price was down 26.7% to $10.88 in early morning trading.

The technology company’s Q4 revenues increased to $58.8 million, up from $48.3 million in the same quarter 2008. Net loss for the quarter was $68,000, or $0.00 per diluted share, compared with net income of $2.7 million, or $0.06 per diluted share, in the same period last year.

Phase Forward attributed the drop in profitability to impairment charges and acquisition costs. The company acquired Waban Software and Maaguzi last year, as well as Covance’s interactive voice and web response services business.

Full-year revenues in 2009 were $213.3 million, up 25% from $170.2 in 2008. Net income for the year was $8 million, or $0.18 per diluted share, compared with $13.8 million, or $0.32 per diluted share, in 2008.

“2009 was one of the most important years in the history of our company,” said Bob Weiler, chairman and CEO, in a statement. “As we begin 2010, we expect Phase Forward to deliver solid financial results, characterized by low to mid-teen revenue growth and a continuation of the recent trend of margin expansion.”
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.